HSAPAY ’s Post

The 10 biggest biopharma companies have all reported Q1 results, and they earned ~$120 billion in revenue. Here is some context behind what drove the biggest increases and declines: 1. Three companies achieved growth of >20%. For Lilly and Novo, it was the continued ramp up of their GLP-1s, which are still in the early innings of their growth story. Amgen's growth was driven by its $28B acquisition of Horizon, without which growth would have been a more modest 6%. 2. Several companies continued to face lingering after-effects from Covid: Pfizer was the biggest, but J&J and Roche also had larger than usual declines thanks to Covid-product sales trailing off. Excluding the decline in Covid vaccine and Paxlovid sales, Pfizer's revenue actually grew 11%, which indicates future quarters will see more positive results. 3. AbbVie managed to keep sales flat, despite facing significant disruption to its biggest-selling medicine, Humira. Humira began to face full competition in the US last year, but strong sales increases of its other immunology medicines Skyrizi and Rinvoq enabled AbbVie to keep immunology and overall revenues essentially unchanged, showing the benefits of its years-long work to diversify its pipeline.

#Pharma's reputation falls for the first time since the #pandemic-era. A few months ago, I had the opportunity to exchange views with Paul Simms on why our industry does not have a better image and what we can do about it. Issues such as #pricing, patient #involvement in R&D and #access to medicines remain points of criticism from patient groups. Here is an interesting article by Nick Paul Taylor on #FiercePharma. What do you think is needed to improve the reputation of pharmaceutical companies?

Very good summary Arjun Murthy! It will be important to see the impact of GLP-1 Drug on the economies from the adverse events perspective and at the same time it will be important to see how companies such as NovoNordisk and Eli Lilly manage demand for these drugs . One of the most encouraging findings about GLP-1s in clinical trials so far has been the relative absence of serious side effects but we need to conduct further studies for the global population!

This is very interesting to see the growth in revenue, while seeing how some of these companies are positioning.

The FDA’s Accelerated Approval Program (AAP) has been a lifeline for patients with serious and often life-threatening conditions, providing faster access to critical therapies that offer hope where none may have existed. Since its inception, the program has enabled the approval of over 300 drugs, offering patients more time and, in many many cases, improved quality of life. There appears to be an escalating critique of the AAP from some in Congress. While the program is essential, there’s room for thoughtful, well considered amendments. Minor amendments can help ensure that the AAP continues to serve patients while addressing valid stakeholder concerns: 1. Enhanced Transparency and Oversight: By increasing the transparency of trial results and improving communication with the public and stakeholders, the FDA and pharmaceutical companies can build greater trust in the program’s process and outcomes. 2. Flexible Pricing Models: Exploring pricing strategies that reflect the provisional nature of accelerated approval drugs until confirmatory data is available could help address concerns from payers and healthcare economists about cost burdens. The AAP has been a beacon of hope for patients facing diseases like cancer, ALS, and rare genetic conditions. Rather than dismantling it, we should make thoughtful adjustments that satisfy stakeholders while maintaining rapid access to life-saving treatments. Smart reforms protect the original intent of the legislation and ensures that patients continue to benefit from the innovations it enables. #AcceleratedApproval #FDA #PatientAccess #HealthcareInnovation #Oncology #RareDiseases #LifeSavingTherapies #PublicHealth. Mikael Dolsten, Pfizer, Pfizer Medical, #pfizercolleague, The Janssen Pharmaceutical Companies of Johnson & Johnson, Novo Nordisk, Otsuka Pharmaceutical Co., Ltd., ONO PHARMA USA, ONO PHARMACEUTICAL CO., LTD., Daiichi Sankyo US, Daiichi Sankyo, Akira Morikawa, Roche, Avidity Biosciences, Inc., Genentech, Eli Lilly and Company, Dicerna Pharmaceuticals, Inc., Johnson & Johnson, Amgen, Sanofi, CSL, CSL Plasma, CSL Vifor, Takeda

AstraZeneca Q3 Non-GAAP EPS of $2.08 beats by $1.05. Revenue of $13.57B (+18.1% Y/Y) beats by $490M. Total Revenue growth from Oncology was 22%, CVRM 21%, R&I 24% and Rare Disease 14% ‒ Core Product Sales Gross Margin3 of 82% ‒ Core Operating Margin of 32% ‒ Core Tax Rate of 20% ‒ Core EPS increased 11% to $6.12. In the prior year period, Core EPS included gains totalling $953m from the disposal of Pulmicort Flexhaler US rights and updated contractual arrangements for Beyfortus. FY guidance: Total Revenue is expected to increase by a high teens percentage (previously a mid teens percentage). Core EPS is expected to increase by a high teens percentage (previously a mid teens percentage). “Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 2024 guidance." said Pascal Soriot, CEO. Contact us today, and let us demonstrate how can elevate your portfolio to new levels Contact Us: https://lnkd.in/gy7_gSAb Website: alphabinwanicapital.com Free Newsletter: bit.ly/AlgoNewsletter #Investing #ThematicInvesting #AI #AZN

📊 Earnings Season Update: AstraZeneca vs. Sanofi 📊 The second week of Q2 2024’s earnings season brought mixed reactions from investors for AstraZeneca PLC and Sanofi, reflecting a similar trend to the previous week’s responses to Novartis AG and Johnson & Johnson. 🔬 AstraZeneca Highlights: ▫ Revenue Growth: Q2 revenues up 13% YoY and 2% QoQ, beating estimates by 3%. Despite this, the stock dropped initially by 4% and closed down by 2%. ▫ Oncology Sales: 22% YoY growth in oncology sales, making up 41% of total revenues. ▫ Other Categories: Strong performance in smaller segments like vaccines (+35%) and respiratory therapies (+29%), but these contribute less to total revenue. ▫ China Market: Revenue from China (13% of total) grew 13% YoY but fell 7% QoQ. ▫ Enhertu: Sales growth of 40% YoY but only 2% QoQ, missing estimates by 5%. 💊 Sanofi Highlights: ▪ Revenue Growth: Q2 revenues grew 8% YoY and 3% QoQ, beating estimates by 4%. The stock rose 4%. ▪ Earnings Forecast: Raised earnings forecast to flat growth. ▪ Dupixent Sales: 29% YoY growth, making up 31% of total sales, beating estimates by 5%. ▪ China Market: 7% of total revenue, with a 3% YoY decline. ▪ Beyfortus Prospects: Anticipated blockbuster RSV antibody, despite a seasonal sales drop in Q2. ▪ Consumer Division Spin-off: Positive investor sentiment around the upcoming Opella spin-off. 🔍 Key Takeaway: AstraZeneca faced mixed reactions due to its China exposure and flat Enhertu growth, while Sanofi’s strong performance and strategic moves were well-received by investors. For deeper insights, subscribe to SCRIP! https://lnkd.in/ezf9mttv #EarningsSeason #Pharma #AstraZeneca #Sanofi #InvestorUpdates #Pharmaceuticals #Citeline

Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth beyond 2030, the Company will continue investing in transformative new technologies and platforms that will shape the future of medicine. AstraZeneca will maintain its strategic commitment to R&D while focusing on productivity throughout the Company, driving operating leverage and enabling the delivery of its ambition for a mid-30s percentage Core operating margin by 2026. Beyond 2026, Core operating margin will be influenced by portfolio evolution and the company will target at least the mid-30s percentage range. Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for $80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade.” As AstraZeneca continues to grow across all therapy areas, it will continue to decouple its carbon emissions from its increase in revenue. The Company has already reduced its greenhouse gas emissions (Scopes 1 and 2) by 68% from its 2015 baseline while growing Total Revenue by 85% over the same period. By 2026 the Company will be carbon zero for Scope 1 and 2 emissions and by 2030 halve its Scope 3 emissions, on the way to science-based net zero by 2045 at the latest. #AstraZeneca #WhatScienceCanDo

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

AstraZeneca has become Britain’s first £200bn company following a 20pc rally in its share price since the start of the year. Shares in the pharmaceutical business rose 1.1pc yesterday to value the company at £200.3bn. AstraZeneca’s stock has surged so far this year amid strong sales of its roster of cancer and rare disease ­medicines. The drug company jumped ahead of Shell in April to become the most valuable business on the FTSE 100. AstraZeneca surpassed its long-term revenue targets last year, generating $45.8bn (£35.7bn) of sales compared with $25.7bn in 2014.  It said in May it was now targeting annual revenues of $80bn by 2030, claiming it was embarking on a “new era of growth”. Pascal Soriot, the AstraZeneca chief executive, said many of the treatments it was developing had the potential to generate more than $5bn of revenue in a year. It is aiming to launch a further 20 new medicines before the end of the decade. As part of this push, AstraZeneca struck a £1.6bn deal in November for an experimental weight loss pill being developed by Chinese biotech company Eccogene. Full article: https://lnkd.in/eD8S3WvK